In the past decades evidence has accumulated that women with reproductive and pregnancy-related disorders are at increased risk of developing cardiovascular disease (CVD) in the future. Up to now there is no standardised follow-up of these women becausee guidelines on cardiovascular risk management for this group are lacking. However, early identification of high-risk populations followed by prevention and treatment of CVD risk factors has the potential to reduce CVD incidence. Therefore, the Dutch Society of Obstetrics and Gynaecology initiated a multidisciplinary working group to develop a guideline for cardiovascular risk management after reproductive and pregnancy-related disorders.
Methods
The guideline addresses the cardiovascular risk consequences of gestational hypertension, preeclampsia, preterm delivery, small-for-gestational-age infant, recurrent miscarriage, polycystic ovary syndrome and premature ovarian insufficiency. The best available evidence on these topics was captured by systematic review. Recommendations for clinical practice were formulated based on the evidence and consensus of expert opinion. The Dutch societies of gynaecologists, cardiologists, vascular internists, radiologists and general practitioners reviewed the guideline to ensure support for implementation in clinical practice.
Results
For all reproductive and pregnancy-related disorders a moderate increased relative risk was found for overall CVD, except for preeclampsia (relative risk 2.15, 95% confidence interval 1.76–2.61).
Conclusion
Based on the current available evidence, follow-up is only recommended for women with a history of preeclampsia. For all reproductive and pregnancy-related disorders optimisation of modifiable cardiovascular risk factors is recommended to reduce the risk of future CVD.
World Health Organization. Global status report on noncommunicable diseases, Geneva: WHO, 2010.
3.
CapewellSHayesDKFordES. Life-years gained among US adults from modern treatments and changes in the prevalence of 6 coronary heart disease risk factors between 1980 and 2000. Am J Epidemiol2009; 170: 229–236.
4.
BellamyLCasasJPHingoraniAD. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ2007; 335: 974–974.
5.
Rich-EdwardsJWFraserALawlorDA. Pregnancy characteristics and women’s future cardiovascular health: an underused opportunity to improve women's health?Epidemiol Rev2013; 36: 57–70.
6.
SattarN. Do pregnancy complications and CVD share common antecedents?Atheroscler Suppl2004; 5: 3–7.
7.
De VosMDevroeyPFauserBC. Primary ovarian insufficiency. Lancet2010; 376: 911–921.
8.
FauserBCTarlatzisBCRebarRW. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril2012; 97: 28–38.e25.
9.
YoungBHackerMRRanaS. Physicians’ knowledge of future vascular disease in women with preeclampsia. Hypertens Pregnancy2012; 31: 50–58.
10.
NijdamMETimmermanMRFranxA. Cardiovascular risk factor assessment after pre-eclampsia in primary care. BMC Fam Pract2009; 10: 77–2296–10-77.
11.
SpaanJPeetersLSpaandermanM. Cardiovascular risk management after a hypertensive disorder of pregnancy. Hypertension2012; 60: 1368–1373.
12.
CusimanoMCPudwellJRoddyM. The maternal health clinic: an initiative for cardiovascular risk identification in women with pregnancy-related complications. Am J Obstet Gynecol2014; 210: 438.e1–438.e9.
13.
MoscaLBenjaminEJBerraK. Effectiveness-based guidelines for the prevention of cardiovascular disease in women – 2011 update: a guideline from the American Heart Association. Circulation2011; 123: 1243–1262.
14.
BushnellCMcCulloughLDAwadIA. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke2014; 45: 1545–1588.
TranquilliALDekkerGMageeL. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens2014; 4: 97–104.
17.
BouthoornSHGaillardRSteegersEA. Ethnic differences in blood pressure and hypertensive complications during pregnancy: the Generation R Study. Hypertension2012; 60: 198–205.
WangIKChangSNLiaoCC. Hypertensive disorders in pregnancy and preterm delivery and subsequent stroke in Asian women: a retrospective cohort study. Stroke2011; 42: 716–721.
20.
SkjaervenRWilcoxAJKlungsoyrK. Cardiovascular mortality after pre-eclampsia in one child mothers: prospective, population based cohort study. BMJ2012; 345: e7677–e7677.
21.
Mongraw-ChaffinMLCirilloPMCohnBA. Preeclampsia and cardiovascular disease death: prospective evidence from the Child Health and Development Studies cohort. Hypertension2010; 56: 166–171.
22.
IrgensHUReisaeterLIrgensLM. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ2001; 323: 1213–1217.
23.
HigginsJPThompsonSGSpiegelhalterDJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc2009; 172: 137–159.
24.
LvJNealBEhteshamiP. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis. PLoS Med2012; 9: e1001293–e1001293.
25.
GarovicVDBaileyKRBoerwinkleE. Hypertension in pregnancy as a risk factor for cardiovascular disease later in life. J Hypertens2010; 28: 826–833.
26.
YangQCogswellMEFlandersWD. Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults. JAMA2012; 307: 1273–1283.
27.
DongCRundekTWrightCB. Ideal cardiovascular health predicts lower risks of myocardial infarction, stroke, and vascular death across whites, blacks, and Hispanics: the Northern Manhattan Study. Circulation2012; 125: 2975–2984.
28.
BerksDHoedjesMRaatH. Risk of cardiovascular disease after pre-eclampsia and the effect of lifestyle interventions: a literature-based study. Br J Obstet Gynaecol2013; 120: 924–931.
29.
Regitz-ZagrosekVBlomstrom LundqvistCBorghiC. The task force on the management of cardiovascular diseases during pregnancy of the European Society of Cardiology (ESC). Eur Heart J2011; 32: 3147–3197.
30.
BerkowitzGSPapiernikE. Epidemiology of preterm birth. Epidemiol Rev1993; 15: 414–443.
31.
CatovJMWuCSOlsenJ. Early or recurrent preterm birth and maternal cardiovascular disease risk. Ann Epidemiol2010; 20: 604–609.
32.
LykkeJAPaidasMJDammP. Preterm delivery and risk of subsequent cardiovascular morbidity and type-II diabetes in the mother. Br J Obstet Gynaecol2010; 117: 274–281.
33.
ZeitlinJSzamotulskaKDrewniakN. Preterm birth time trends in Europe: a study of 19 countries. Br J Obstet Gynaecol2013; 120: 1356–1365.
TuckerJMGoldenbergRLDavisRO. Etiologies of preterm birth in an indigent population: is prevention a logical expectation?Obstet Gynecol1991; 77: 343–347.
36.
oldenbergRLCulhaneJFIamsJD. Epidemiology and causes of preterm birth. Lancet2008; 371: 75–84.
37.
BonamyAKParikhNICnattingiusS. Birth characteristics and subsequent risks of maternal cardiovascular disease: effects of gestational age and fetal growth. Circulation2011; 124: 2839–2846.
38.
HeidaKYVelthuisBKOudijkMA. Cardiovascular disease risk in women with a history of spontaneous preterm delivery: a systematic review and meta-analysis. Eur J Prev Cardiol2015; 23: 253–263.
39.
ShionoPHKlebanoffMARhoadsGG. Smoking and drinking during pregnancy: their effects on preterm birth. JAMA1986; 255: 82–84.
40.
McGorrianCYusufSIslamS. Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk score. Eur Heart J2011; 32: 581–589.
41.
BakketeigLSBjerkedalTHoffmanHJ. Small-for-gestational age births in successive pregnancy outcomes: results from a longitudinal study of births in Norway. Early Hum Dev1986; 14: 187–200.
42.
VoskampBJKazemierBMRavelliAC. Recurrence of small-for-gestational-age pregnancy: analysis of first and subsequent singleton pregnancies in The Netherlands. Am J Obstet Gynecol2013; 208: 374.e1–374.e6.
43.
BarkerDJ. Fetal origins of coronary heart disease. BMJ1995; 311: 171–174.
44.
LykkeJAPaidasMJTricheEW. Fetal growth and later maternal death, cardiovascular disease and diabetes. Acta Obstet Gynecol Scand2012; 91: 503–510.
45.
NilssonPMLiXSundquistJ. Maternal cardiovascular disease risk in relation to the number of offspring born small for gestational age: national, multi-generational study of 2.7 million births. Acta Paediatr2009; 98: 985–989.
46.
OlsenIEGrovemanSALawsonML. New intrauterine growth curves based on United States data. Pediatrics2010; 125: e214–224.
47.
ManorOKoupilI. Birth weight of infants and mortality in their parents and grandparents: the Uppsala Birth Cohort Study. Int J Epidemiol2010; 39: 1264–1276.
48.
BonamyAKParikhNICnattingiusS. Birth characteristics and subsequent risks of maternal cardiovascular disease: effects of gestational age and fetal growth. Circulation2011; 124: 2839–2846.
49.
ThompsonJMClarkPMRobinsonE. Risk factors for small-for-gestational-age babies: the Auckland Birthweight Collaborative Study. J Paediatr Child Health2001; 37: 369–375.
50.
PrescottEHippeMSchnohrP. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ1998; 316: 1043–1047.
51.
BukowskiRDavisKEWilsonPW. Delivery of a small for gestational age infant and greater maternal risk of ischemic heart disease. PLoS One2012; 7: e33047–e33047.
52.
OdegardRAVattenLJNilsenST. Preeclampsia and fetal growth. Obstet Gynecol2000; 96: 950–955.
53.
LykkeJALanghoff-RoosJLockwoodCJ. Mortality of mothers from cardiovascular and non-cardiovascular causes following pregnancy complications in first delivery. Paediatr Perinat Epidemiol2010; 24: 323–330.
54.
Nybo AndersenAMWohlfahrtJChristensP. Maternal age and fetal loss: population based register linkage study. BMJ2000; 320: 1708–1712.
55.
ReganLRaiR. Epidemiology and the medical causes of miscarriage. Baillieres Best Pract Res Clin Obstet Gynaecol2000; 14: 839–854.
56.
EmpsonMLassereMCraigJ. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev20052, CD002859–CD002859.
57.
LongBRLeyaF. The role of antiphospholipid syndrome in cardiovascular disease. Hematol Oncol Clin North Am2008; 22: 79–94, vi–vii.
58.
Practice Committee of American Society for Reproductive Medicine. Obesity and reproduction: an educational bulletin. Fertil Steril2008; 90: S21–29.
59.
Garcia-EnguidanosACalleMEValeroJ. Risk factors in miscarriage: a review. Eur J Obstet Gynecol Reprod Biol2002; 102: 111–119.
60.
KharazmiEDossusLRohrmannS. Pregnancy loss and risk of cardiovascular disease: a prospective population-based cohort study (EPIC-Heidelberg). Heart2011; 97: 49–54.
61.
MarchWAMooreVMWillsonKJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod2010; 25: 544–551.
62.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod2004; 19: 41–47.
63.
MoranLJMissoMLWildRA. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update2010; 16: 347–363.
64.
WildSPierpointTMcKeigueP. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxford)2000; 52: 595–600.
65.
de WildeMAVeltman-VerhulstSMGoverdeAJ. Preconception predictors of gestational diabetes: a multicentre prospective cohort study on the predominant complication of pregnancy in polycystic ovary syndrome. Hum Reprod2014; 29: 1327–1336.
66.
BellamyLCasasJPHingoraniAD. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet2009; 373: 1773–1779.
67.
TanYYGastGCvan der SchouwYT. Gender differences in risk factors for coronary heart disease. Maturitas2010; 65: 149–160.
68.
Roeters van LennepJEHeidaKYBotsML. Cardiovascular disease risk in women with premature ovarian insufficiency: a systematic review and meta-analysis. Eur J Prev Cardiol2016; 23: 178–186.
69.
StuenkelCA. Cardiovascular risk and early menopause: cause or consequence?Menopause2012; 19: 1067–1069.
70.
MansonJEChlebowskiRTStefanickML. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women’s health initiative randomized trials. JAMA2013; 310: 1353–1368.
71.
LokkegaardEJovanovicZHeitmannBL. The association between early menopause and risk of ischaemic heart disease: influence of hormone therapy. Maturitas2006; 53: 226–233.
72.
JacobsenBKKnutsenSFFraserGE. Age at natural menopause and total mortality and mortality from ischemic heart disease: the Adventist Health Study. J Clin Epidemiol1999; 52: 303–307.
73.
BodnarLMCatovJMKlebanoffMA. Prepregnancy body mass index and the occurrence of severe hypertensive disorders of pregnancy. Epidemiology2007; 18: 234–239.
74.
van RijnBBNijdamMEBruinseHW. Cardiovascular disease risk factors in women with a history of early-onset preeclampsia. Obstet Gynecol2013; 121: 1040–1048.
75.
SmithGNWalkerMCLiuA. A history of preeclampsia identifies women who have underlying cardiovascular risk factors. Am J Obstet Gynecol2009; 200: 58.e1–58.e8.
76.
van BaarenGJHermesWFranxA. Cost-effectiveness analysis of cardiovascular risk factor screening in women who experienced hypertensive pregnancy disorders at term. Pregnancy Hypertens2014; 4: 264–270.
77.
AuneDSaugstadODHenriksenT. Physical activity and the risk of preeclampsia: a systematic review and meta-analysis. Epidemiology2014; 25: 331–343.
78.
ButlerCLWilliamsMASorensenTK. Relation between maternal recreational physical activity and plasma lipids in early pregnancy. Am J Epidemiol2004; 160: 350–359.
RobergeSSibaiBMcCaw-BinnsA. Low-dose aspirin in early gestation for prevention of preeclampsia and small-for-gestational-age neonates: meta-analysis of large randomized trials. Am J Perinatol2016; 33(8): 781–5.
81.
RobergeSGiguereYVillaP. Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am J Perinatol2012; 29: 551–556.
82.
ShimSMYunYUKimYS. Folic acid alone or multivitamin containing folic acid intake during pregnancy and the risk of gestational hypertension and preeclampsia through meta-analyses. Obstet Gynecol Sci2016; 59: 110–115.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
